To test whether Mek inhibition promotes degradation of ErbB2 in the lysosomes of detached breast cancer cells we treated detached BT474 cells with selumetinib in the absence and in the presence of a lysosomal inhibitor Bafilomycin A1 [40, 41]. The gene discussed is MAP2K7; the disease is breast carcinoma.